Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dutogliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 18/20 | 1.00 |
| ▸ | FAP | Q12884 | 19/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 1.00 |
| ▸ | DPP7 | Q9UHL4 | 11/20 | 0.72 |
| ▸ | PREP | P48147 | 7/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dutogliptin SCHEMBL5502671 | 1.00 | FAP (1.00) | FAPDPP4DPP8DPP9DPP7 | |
| Dutogliptin SCHEMBL1236486 | 1.00 | FAP (1.00) | FAPDPP4DPP8DPP9DPP7 | |
| Dutogliptin SCHEMBL164106 | 1.00 | FAP (1.00) | FAPDPP4DPP8DPP9DPP7 | |
| Dutogliptin SCHEMBL5526847 | 1.00 | FAP (1.00) | FAPDPP4DPP8DPP9DPP7 | |
| Dutogliptin SCHEMBL8030287 | 1.00 | FAP (1.00) | FAPDPP4DPP8DPP9DPP7 | |
| SCHEMBL13713813 | 0.94 | FAP (0.88) | FAPDPP4DPP8DPP9DPP7 | |
| SCHEMBL7901017 | 0.94 | FAP (0.88) | FAPDPP4DPP8DPP9DPP7 | |
| SCHEMBL13997343 | 0.94 | FAP (0.88) | FAPDPP4DPP8DPP9DPP7 | |
| SCHEMBL7898224 | 0.94 | FAP (0.88) | FAPDPP4DPP8DPP9DPP7 | |
| SCHEMBL7896597 | 0.92 | FAP (0.85) | FAPDPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317143-A9 | BORONIC ESTER PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2021-10-14 | — | — | US | disclosed |
| US-20200369685-A1 | BORONIC ESTER PRODRUGS AND USES THEREOF | MASSACHUSETTS INST TECHNOLOGY (US) | 2020-11-26 | — | — | US | disclosed |
| US-20100087658-A1 | METHODS AND INTERMEDIATES FOR SYNTHESIS OF SELECTIVE DPP-IV INHIBITORS | PHENOMIX CORPORATION (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087658-A1 | METHODS AND INTERMEDIATES FOR SYNTHESIS OF SELECTIVE DPP-IV INHIBITORS | PHENOMIX CORPORATION (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2008109681-A2 | METHODS AND INTERMEDIATES FOR SYNTHESIS OF SELECTIVE DPP-IV INHIBITORS | PHENOMIX CORPORATION (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369685-A1 | BORONIC ESTER PRODRUGS AND USES THEREOF | BRCA1, BTD, BCHE | DPP4 2162/4885FAP 130/4885DPP8 1490/4885 |
| US-20100087658-A1 | METHODS AND INTERMEDIATES FOR SYNTHESIS OF SELECTIVE DPP-IV INHIBITORS | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 43/4885DPP8 4/4885 |
| US-20210317143-A9 | BORONIC ESTER PRODRUGS AND USES THEREOF | BRCA1, BTD, BCHE | DPP4 2162/4885FAP 130/4885DPP8 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.